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The pathogenesis of obesity (OB) andmetabolic syndrome (MetS) implies free radical-, oxidized lipid- (LOOH-), and inflammatory
cytokine-mediated altered pathways in target organs. Key elements of the transition from benign OB to unhealthy OB+MetS
remain unclear. Here, we measured a panel of redox, antioxidant, and inflammation markers in the groups of OB patients (67
with, 45 without MetS) and 90 controls. Both OB groups displayed elevated levels of adipokines and heavy oxidative stress
(OS) evidenced by reduced levels of glutathione, downregulated glutathione-S-transferase, increased 4-hydroxynonenal-protein
adducts, reactive oxygen species, and membrane-bound monounsaturated fatty acids (MUFA). Exclusively in OB+MetS, higher-
than-normal glutathione peroxidase activity, tumor necrosis factor-𝛼, and other proinflammatory cytokines/chemokines/growth
factors were observed; a combination of high adipokine plasminogen activator inhibitor-1 andMUFAwas consistent with increased
cardiovascular risk. The uncomplicated OB group showed features of adaptation to OS such as decreased levels of vitamin E,
activated superoxide dismutase, and inhibited catalase, suggesting H
2
O
2
hyperproduction. Proinflammatory cytokine pattern was
normal, except fewmarkers like RANTES, a suitable candidate for therapeutic approaches to prevent a setting ofMetS by inhibition
of LOOH-primed leukocyte chemotaxis/recruitment to target tissues.
1. Introduction
The constant growth of obesity pandemic has fostered the
research of reliable biomarkers for routine diagnosis, able to
assess the severity of the underlying metabolic impairment,
to predict risk of the wide array of multiorgan complications,
and to provide solid molecular basis for innovative therapeu-
tic approaches [1–3]. Distinctive ties between metabolic dys-
function and immune system alterations have also produced
relevant achievements, leading to the classification of the
adipose tissue as an effective immunoendocrinological organ
[4–6]. Metabolic syndrome (MetS) is the most distinctive
condition featuring “nonbenign obesity” (morbid obesity)
[7, 8], which encompasses the health-impairing forms of
obesity [9–11]. The different criteria are adopted worldwide,
also on ethnic basis, to diagnose MetS; all include the
key parameters of fasting plasma glycemia, total and HDL
cholesterol levels, fasting triglyceride levels, blood pressure,
waist circumference, body mass index (BMI), and insulin
resistance [7, 12–15].
Various combinations of these altered parameters have
been unequivocally related to the individual higher risk of
Hindawi Publishing Corporation
Oxidative Medicine and Cellular Longevity
Volume 2015, Article ID 490613, 14 pages
http://dx.doi.org/10.1155/2015/490613
2 Oxidative Medicine and Cellular Longevity
endocrinological [16, 17], hepatic [18, 19], cardiovascular [20,
21], neurological [22, 23], and ultimately oncological [24]
outcomes. More recently the immunological state, namely,
the altered transcription levels and/or the altered concentra-
tions levels of several systemic proinflammatory cytokines,
chemokines, and growth factors, as well as adipose-tissue-
specific adipokines, have gained focus as key parameters
driving mere overweight into a MetS [25]. Their alterations
have been directly correlated with lipid metabolism, adi-
pogenesis and fat distribution, adipocyte metabolism and
function, glucose uptake abnormalities, insulin secretion and
resistance, appetite and satiety, energy expenditure, endothe-
lial function, hemostasis, blood pressure, energy metabolism
in insulin sensitive tissues, and immune cell migration into
adipose tissue [26–30].
The role of systemic redox state and of antioxidant (AO)
imbalance has also been studied in obesity in terms of molec-
ular mechanisms of disease (for recent review see [31]) and
of nutritional intervention protocols aimed at weight control
and normalization of metabolic parameters (for review see
[32]). In particular, the etiological relevance of excessive
reactive-species-mediated oxidation of lipids, carbohydrates,
and proteins in the different organs targeted by MetS has
been extensively described [33–35]. The current diagnos-
tic guidelines of MetS and morbid obesity are essentially
based on type II diabetes protocols and traditionally employ
combined approaches, that is, the anthropometric profile
(height, weight, waist/hip/arm circumference, etc.), mainly
reported as BMI index [36], coupled with the assessment of
clinical laboratory parameters connected with glucose and
lipid metabolism [7, 12–15], hormone status [12], routine
protein markers of inflammation [37], bone, hepatic, and
renal markers [38, 39]. The reliability of BMI and waist
circumference parameters is currently being discussed, as
unable to correlate with the individual levels of lipid and
glucose dysmetabolism or of chronic inflammation [40, 41].
Overcoming biopsy invasiveness, technology-assisted nonin-
vasive evaluation methods of fat and lean mass, of liver or
cardiac fat, and so forth have been introduced as additional
clinical parameters correlating with severity of obesity [39,
42]. Conversely, the laboratory blood test protocols for MetS
and obesity have not been updated with clinical research
outcomes. Thus far, neither the proinflammatory cytokines
and adipokines panels, in effect requiring elevated costs, nor
the redox parameters, more easily measurable on a routine
basis, have been examined extensively in the different obese
types.
In the attempt to contribute to the ongoing efforts for
the identification of new pathologically relevant molecular
markers of obese morbidity, we attempted here to identify
possible significative alterations of a panel of 55 metabolic
blood markers of redox status, nutritional and endogenous
AO/free radical-detoxifying defenses, and unsaturated lipid
quality and oxidation grade, in a group of 112 Italian Cau-
casian obese patients, of which 67 with obese state aggravated
by MetS, as compared with a control group of 90 healthy
subjects. In addition, the concurrent analysis of a panel
of 37 serum cytokines and adipokines enabled a compar-
ative evaluation of the chronic proinflammatory levels in
the two obesity subgroups. Ultimately, the study protocol
aimed at identifying possible specific redox-relatedmetabolic
and immunologic patterns marking the transition from a
state of “healthy” obesity to morbid obesity with MetS and
increased type II diabetes risk. The selection of a specific
panel of reliable molecular determinants for this transition
bears promising implications for diagnosis, risk prevention,
and follow-up of obese subjects with different degrees of
impaired metabolism and possibly will provide new hints for
future treatment innovation.
2. Materials and Methods
2.1. Patients. The study enrolled a group of 112 Italian Cau-
casian obese subjects at “Umberto I” Polyclinic, and IDI
IRCCS-Istituto Dermopatico dell’Immacolata, Rome, Italy.
The patients, included on the basis of their consecutive
attendance to the obesity outpatient facilities of the two
centers, displayed the following sex distribution: 100 females
(89%) and 12 males (11%). The study protocol was reviewed
and approved by the hospital Ethical Committee Board IDI
IRCCS n.121/CE/2008. Of the patient group, 𝑛 = 67 sub-
jects were diagnosed with metabolic syndrome (OB w.MetS,
59F/8M, age: m ± S.D. = 44.4± 12.1) and 𝑛 = 45 did not meet
MetS criteria (OB w.o.MetS, 41F/4M, age: m ± S.D. = 42.6 ±
11.7), as determined according to revised NCEP ATP III (US
National Cholesterol Education Program, Adult Treatment
Panel) criteria, cut-off value for abdominal obesity 94 cm for
men and 80 cm for women [12]. Patients with overt endocrine
pathology, acute illnesses, heart diseases, uncontrolled hyper-
tension, current use of hypnotics, or any treatment for breath-
ing disorders were excluded from enrollment.
A cohort of 90 healthy age- and sex-matched subjects
were enrolled as the control group (CTR, agem± S.D. = 42.5±
11.7), 83 females (92%) and 7 males (study protocol approval
by IDI IRCCS Ethical Committee, n.52/CE/2010), according
to the established criteria of (i) absence of any clinically
diagnosed disease, in particular allergic or immunologic dis-
turbances and (ii) whole blood total production of reactive
oxygen and nitrogen species (ROS/RNS) below 650 cps/𝜇L,
as determined by luminol-dependent chemiluminescent
response to phorbol 12-myristate 13-acetate (PMA) [43].
No patients/controls entering the study had taken any
drugs or nutraceutical supplements known to interfere with
metabolizing/AO enzymes activity since at least six weeks, at
the time of blood sampling. No alcohol- or drug-abusers were
present in any of the three cohorts studied. All subjects gave
their informed consent to personal and anamnestic data col-
lection, blood sampling for the specific sets of analyses, and
blood fractions banking. Anthropometric data and detailed
clinical history were registered by trained medical personnel.
Routine blood parameters examined in the obese patient
including fasting total cholesterol (CHOL), low density
lipoproteins (LDL), high density lipoproteins (HDL), triglyc-
erides (TG), glucose, insulin, C-reactive protein (CRP), alka-
line phosphatase (ALP), aspartate aminotransferase (AST),
alanine aminotransferase (ALT), gamma glutamyltransferase
(gamma GT) were evaluated with routine clinical chemistry
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laboratory methods. BMI was calculated as weight in kg
divided by the square of height in meters (kg/m2) [44].
Fatmass wasmeasured by dual energy X-ray absorptiom-
etry (DEXA) (Hologic Inc., Bedford,MA,USA,QDR4500W,
S/N47168) [42] by one single experienced technician. Specific
delimiters for regional analysis were determined by standard
software (Hologic Inc., QDR 4500W S/N 47168 VER. 11.2).
Total body fat mass was expressed in percentage of total
weight.
2.2. Reagents and Assay Kits. Majority of chemical reagents,
HPLC standards, mediums, and fluorogenic probes were
from Sigma Chemical Co. (St. Louis, MO, USA); kits for
enzyme activity assays were from Cayman Chem. Co. (Ann
Arbor, MI, USA); Western blot reagents and antibodies were
from Invitrogen (Milan, Italy), Millipore (Billerica, MA),
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA), Bio-Rad
Laboratories, Inc. (Hercules, CA, USA), and Amersham
Biosciences (Milan, Italy).
2.3. Redox and Oxidation Marker Studies. Complete dif-
ferential blood cell counts and metabolic analyses were
performed on fresh ethylenediaminetetraacetic acid (EDTA)-
anticoagulated venous blood of 12 hr-fasting subjects. Bio-
chemical assays were performed on peripheral blood plasma
or erythrocytes (RBC) either immediately (ATP, glutathione,
and coenzyme Q
10
) or within 72 hr on sample aliquots stored
at −80∘C under argon. Whole blood luminol-dependent
chemiluminescence (CL, expressed in counts per second,
cps/𝜇L) response to PMA was quantified by a Victor2 1420
multilabel counter, equipped with Wallac 1420 software
(Perkin Elmer, MA, USA) according to [43]; levels of nitrites/
nitrates (NO
2
−/NO
3
−, expressed as 𝜇mol/L) were measured
spectrophotometrically by Griess reagent [45]. Protein con-
tent was measured according to Bradford, using Bio-Rad
microplate assay kit. Plasmatic total antioxidant capac-
ity (TAC, nmol/L) was determined spectrophotometrically
according to [46]. Reduced and oxidized glutathione (GSH,
GSSG, mg/L) levels in erythrocytes [47], reduced and oxi-
dized coenzyme Q
10
(CoQ
10
H
2
, CoQ
10
, 𝜇g/L), and 𝛼-tocop-
herol (ALPHA-TOC, mg/L) levels in plasma were quantified
by HPLC equipped with array photodiode and electrochem-
ical detection as described previously [48]. Activities of
CuZn superoxide dismutase (CuZn-SOD, U/g prot. (pro-
tein)) [49], catalase (CAT, U/g prot.) [50], glutathione S-
transferase (GST, U/mg Hb (haemoglobin)) [51], and glu-
tathione peroxidase (GPX, U/mg Hb) [52] in erythrocytes
were measured spectrophotometrically. Differences in 4-
hydroxynonenal protein adducts (4-HNE PA) levels in the
plasma of obese patients and controls were assessed with
semiquantitative approach by Western blot analysis, as pre-
viously described [53]. Briefly, plasma samples (60 𝜇g prot.)
were diluted in reducing sample buffer and boiled for 10min.
Samples were resolved on a 4–20% sodium dodecyl sulphate-
polyacrylamide gradient gel (Invitrogen, Milan, Italy) and
electrotransferred onto nitrocellulose membranes. Loading
control was performed with ponceau staining. After blocking
in 3% fat-free milk in phosphate buffered saline solution,
the membranes were incubated overnight at 4∘C with goat
anti-HNE polyclonal antibodies (Millipore, Billerica, MA) at
1 : 3000 dilution. After washing, mouse anti-goat horseradish
peroxidase-conjugated antibodies (Santa Cruz Biotechnol-
ogy, Inc., Santa Cruz, CA) were used as secondary antibodies.
Membranes were processed with the enzymatic chemilumi-
nescence solution (ECL, Immune-Star HRP Substrate Kit,
Bio-Rad) and exposed to photographic film (Hyperfilm
ECL, Life Science, Amersham Biosciences, Milan, Italy),
according tomanufacturer recommendations. Band densities
were quantified using the National Institute for Health image
shareware. Results of three independent experiments were
expressed in arbitrary units (usually, corresponding to the
𝜇M range), as mean values ± SD.
2.4. Erythrocyte Membrane Fatty Acid Profiling. The fatty
acid (FA) pattern of erythrocyte membrane phospholipids
was analyzed on a subgroup of patients and controls by
gas-chromatography coupled with mass spectrometry with
the selected ion monitoring technique, set to identify C16:0,
C16:1, C18:0, C18:1cis, C18:1trans, C18:2𝜔6, C18:3𝜔6, C20:4𝜔6,
C20:5𝜔3, C22:4𝜔3, C22:5𝜔3, and C22:6𝜔3 peaks [54]. Results
were expressed as percentage of the total fatty acid content
of membrane phospholipids for saturated (SAT), mono-
unsaturated FA (MUFA), and polyunsaturated FA (PUFA),
as percent values of the single representative FA of the 𝜔-3-
and 𝜔-6-PUFA series and as specific ratios, SAT/MUFA and
𝜔-6-/𝜔-3-PUFA.
2.5. ATP Measurement in Platelet-Enriched Plasma. Adeno-
sine 5󸀠-triphosphate (ATP) levels in activated platelet-
enriched plasma (PRP) was measured with a Biolumines-
cent Assay Kit (Sigma-Aldrich, MO, USA). Fresh EDTA-
anticoagulated bloodwas centrifuged 8min at 1000 g, and the
upper layer without erythrocytes was collected. PRP was kept
at room temperature for analysis. Platelets were activated by
a 5min incubation with thrombin. Results were expressed as
𝜇mol/L (𝜇M).
2.6. Cytokine and Adipokine Plasmatic Profiling. The plasma
levels of 27 cytokines, chemokines, and growth factors inter-
leukin, IL-1𝛽; IL-1ra; IL-2; IL-4; IL-5; IL-6; IL-7; IL-8; IL-
9; IL-10; IL-12; IL-13; IL-15; IL-17; eotaxin; fibroblast growth
factor basic, bFGF; granulocyte-colony stimulating factor,
G-CSF; granulocyte-macrophage colony stimulating factor,
GM-CSF; interferon-𝛾, IFN-gamma; IFN-𝛾-inducible pro-
tein 10, IP-10; monocyte chemoattractant protein-1, MCP-1;
macrophage inflammatory protein 1-𝛼, MIP-1𝛼; macrophage
inflammatory protein 1-𝛽, MIP-1𝛽 (regulated on activation
normal T cell expressed and secreted, RANTES; platelet-
derived growth factor-bb, PDGFbb; tumor necrosis factor-
𝛼, TNF-𝛼; vascular endothelial growth factor, VEGF), and
10 adipokines (C-peptide; ghrelin; gastric inhibitory polypep-
tide, GIP; glucagon-like peptide-1, GLP-1; glucagon; insulin;
leptin; plasminogen activator inhibitor-1, PAI-1 total; resistin;
visfatin) weremeasured simultaneously applyingmultiplexed
Bio-Rad assays, using the Bio- Plex Suspension Array Sys-
tem (Bio-Rad Laboratories, Inc., Hercules, CA, USA) [55].
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Table 1: Biometric and clinical chemistry parameters (mean ± SEM) of the two patient groups under study: obese with metabolic syndrome
(OB w.MetS) and obese without metabolic syndrome (OB w.o.MetS).
Parameter OB w.MetS(𝑛 = 67, 59 F/8 M)
OB w.o.MetS
(𝑛 = 45, 41 F/4 M)
BMI (kg/m2) 41.8 ± 1.5 38.3 ± 1.3∗
WAIST CIRCUMFERENCE (cm) 121.7 ± 2.3 115.0 ± 2.7
FAT MASS (%) 42.2 ± 0.9 42.7 ± 1.3
LEANMASS (%) 57.8 ± 0.9 57.3 ± 1.3
PLASMA TOTAL CHOL (mg/dL) 211.0 ± 7.8 190.8 ± 6.5
PLASMA LDL (mg/dL) 135.2 ± 5.8 119.7 ± 6.8
PLASMA HDL (mg/dL) 42.5 ± 1.3 55.2 ± 2.1#
PLASMA TG (mg/dL) 190.8 ± 15.4 81.9 ± 4.7#
PLASMA TOTAL CHOL/HDL ratio 5.1 ± 0.2 3.59 ± 0.2#
PLASMA TG/HDL ratio 4.71 ± 0.5 1.57 ± 0.1#
FASTING GLUCOSE (mg/dL) 104.8 ± 3.7 86.7 ± 1.9§
FASTING INSULIN (𝜇U/mL) 34.3 ± 3.6 21.5 ± 2.4§
CRP (mg/dL) 1.1 ± 0.2 0.7 ± 0.1
ALP (IU/L) 95.2 ± 7.0 76.3 ± 6.4
AST (IU/L) 27.4 ± 2.6 18.1 ± 1.1§
ALT (IU/L) 43.9 ± 6.5 39.2 ± 16.2
gammaGT (IU/L) 42.9 ± 7.0 20.6 ± 4.3#
#
𝑝 < 0.0001; §𝑝 < 0.001; ∗𝑝 < 0.05.
Abbreviations: BMI (body mass index); CHOL (cholesterol); LDL (low density lipoproteins); HDL (high density lipoproteins); TG (triglycerides); CRP (C-
reactive protein); ALP (alkaline phosphatase), AST (aspartate aminotransferase), ALT (alanine aminotransferase), gamma GT (gamma glutamyltransferase);
U (units); IU (international units).
The assay was performed according to the manufacturer’s
instructions. Cytokine concentrations were expressed in
pg/mL of plasma, and each factor was quantified in the linear
range of its calibration curve using a Bio-Rad array reader.
2.7. Statistical Analysis. Statistical significance of redox and
fatty acid parameters was evaluated using STATISTICA 6.0
program (StatSoft Inc., Tulsa, OK, USA). Normality of data
was checked using the Shapiro-Wilk test. Since the distribu-
tion of the data in the three groups was significantly different
fromnormal, nonparametric statistics were used. Values were
presented as mean, standard error of the mean, and 1.96 ×
standard error of duplicate analyses. Mann-Whitney 𝑈 test
for independent samples was employed for comparison
between case groups and controls. All reported 𝑝 values are
from two-tailed tests, and 𝑝 values of less than 0.05 were
considered to indicate statistical significance. If necessary,
𝑝 values were adjusted for multiple comparisons using the
Bonferroni adjustment.
3. Results
3.1. Anamnestic Data. CTR group mean ± SEM values of
BMIwere 22.5± 0.7 kg/m2; clinical laboratory parameters fell
within normal range (data not shown). Patient self-declared
age of obesity onset was 19±2.1 and 17±2.5 yr., and duration
of obesity statewas 24±2.1 and 19±2.0 yr., respectively, forOB
w.MetS and OB w.o.MetS.The main relevant anthropometric
and routine clinical laboratory parameters examined by
clinicians to set the diagnosis of obesity or of obesity with
MetS, are reported in Table 1. According to the World Health
Organization definition of obesity classes as a function of
BMI [56], obese patients were distributed as follows: 7.8%
overweight (BMI = 25.0–29.9), 23.4% class I (BMI = 30.0–
34.9), 20.3% class II (BMI = 35.0–39.9), and 48.5% class III
(BMI ≥ 40).
3.2. RBC Detoxifying and Antioxidant Enzyme Activities.
Results obtained in the control group and in obese sub-
jects with or without MetS for RBC activities of enzymes
committed to the detoxification of oxygen, nitrogen, and
oxidized lipid reactive species, as well as to antioxidant
functions, are shown in Figure 1. In the OB w.MetS, GPX
activity was increased (𝑝 < 0.01) versus CTR (Figure 1(a)),
with correspondent decrease of GSH content in RBC (𝑝 <
0.01) (Figure 1(e)). In the OB w.o.MetS, no GSH decrease
was observed (Figure 1(e)). GPX activity did not result
hyperactivated versus CTR and was consistently lower than
in the OB w.MetS group (𝑝 < 0.05) (Figure 1(a)). RBC
CuZn-SOD was not elevated in MetS-obese, while it was
significantly increased inOBw.o.MetS versus CTR (𝑝 < 0.01)
(Figure 1(b)). Figure 1(c) shows that CAT activity was signifi-
cantly suppressed in the sameOBw.o.MetS group versus both
CTR and OB w.MetS (𝑝 < 0.01). GST erythrocyte activity
(Figure 1(d)) was markedly lower than CTR (𝑝 < 0.001)
in all obese patients. As a whole, obese subgroups suffered
a depletion of glutathione erythrocyte levels, affecting both
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Figure 1:Metabolic redox parameters: erythrocyte levels of antioxidant/detoxifying enzymatic activities of glutathione peroxidase (a), CuZn-
superoxide dismutase (b), catalase (c), glutathione-S-transferase (d), and reduced, oxidized glutathione (e-f), in the groups of obese patients
with metabolic syndrome (OB w.MetS, 𝑛 = 67) and without metabolic syndrome (OB w.o.MetS, 𝑛 = 45), and of control healthy subjects
(CTR, 𝑛 = 90). Values are represented as mean (◻), standard error of the mean (upper and lower limits of the box), and 1.96 × standard error
(upper and lower whiskers). Intergroup significant differences (𝑝) are indicated in each panel. Abbreviations: GPX (glutathione peroxidase),
CuZnSOD (CuZn-superoxide dismutase); CAT (catalase); GST (glutathione S-transferase); GSH (reduced glutathione); GSSG (oxidized
glutathione); RBC (red blood cells); U (units); prot. (proteins); Hb (haemoglobin). Techniques: spectrophotometric methods (a–d), HPLC
with array photodiode detection (e).
reduced (GSH) and oxidized (GSSG) forms in OB w.MetS
(𝑝 < 0.01) and limited to GSSG in OB w.o.MetS (Figures 1(e)
and 1(f)).
3.3. Plasmatic Oxidation Markers and Antioxidants. Con-
sistent with the depletion of the detoxifying cofactor glu-
tathione, 4-HNE PA levels displayed significant elevation in
the plasma of both obese cohorts (resp., 𝑝 < 0.001 and 𝑝 <
0.0001, resp., in OB w.MetS and OB w.o.MetS), as compared
to healthy normal-weight subjects (Figure 2(a)). Figure 2(b)
shows a representative blot for 4HNE PA in the three study
cohorts. In line, the whole blood luminol-dependent CL
was increased in obese both with and without MetS and
reached the soundest statistical significance versus CTR
(𝑝 < 0.0001) only in the latter group (Figure 2(c)). Plasma
coenzyme Q
10
content (both reduced and oxidized forms)
was unaltered versus CTR in obesity with and without MetS
(data not shown). Vitamin E (𝛼-tocopherol) plasma levels
were significantly lower than CTR values (𝑝 < 0.01) only
in the OB w.o.MetS (Figure 2(d)), consistent with the highly
significant-versus-baseline elevation of blood CL in the same
group (Figure 2(c)). TAC index of plasma antioxidant capac-
ity did not statistically differ among the three groups under
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Figure 2: Metabolic redox parameters: levels of plasma 4-hydroxynonenal protein adducts (a) and a representative blot of the relative gel
bands of samples and of loading control (ponceau staining) (b), of whole blood luminol-dependent chemiluminescence (c), of plasma 𝛼-
tocopherol (d), in the groups of obese patients with metabolic syndrome (OB w.MetS, 𝑛 = 67) and without metabolic syndrome (OB
w.o.MetS, 𝑛 = 45), and of control healthy subjects (CTR, 𝑛 = 90). Values are represented as mean (◻), standard error of the mean (upper and
lower limits of the box), and 1.96 × standard error (upper and lower whiskers). Intergroup significant differences (𝑝) are indicated in each
panel. Abbreviations: 4-HNE PA (4-hydroxynonenal protein adducts); kDa (kiloDalton); CL (luminol-dependent chemiluminescence); cps
(counts per second); ALPHA-TOC (𝛼-tocopherol). Techniques:Western blot (a-b), chemiluminescence (c), andHPLCwith array photodiode
detection (d).
study (data not shown). Plasmatic NO
2
−/NO
3
− levels were
not significantly different among the three study cohorts.
Mean ± S.E. values were CTR 20.7 ± 1.05; OB w.MetS 18.2 ±
1.12, and OB w.o.MetS 15.9 ± 1.44.
3.4. Erythrocyte Membrane Fatty Acid Profiles. Figure 3
describes peculiar alterations of the fatty acid profile of
RBC membrane phospholipids. In both obese subgroups, a
significant increase (𝑝 < 0.05–0.001) of monounsaturated FA
was recorded, expressed as the decreasing ratio SAT/MUFA
(Figure 3(a)). As a whole, 𝜔-3 FA were not decreased in
obese groups, as reported in Figure 3(b), where the ratio 𝜔-
6/𝜔-3 was not significantly increased versus control group.
Nevertheless, Figures 3(c) and 3(d) show that in the OB
w.o.MetS patients the percentage compostion of the most
abundant 𝜔-6 FA, arachidonic acid (C20:4), is significantly
raised (𝑝 < 0.05), whilst the most representative 𝜔-3 FA,
eicosapentaenoic acid (C20:5), is sharply decreased (𝑝 <
0.01).
3.5. Cytokine and Adipokine Plasma Profiles. Of the panel
of ten main plasma adipokines measured, four were signif-
icantly different in the obesity subgroups as compared to
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Figure 3: Selected representative parameters describing fatty acid profile of erythrocyte membrane phospholipids: ratio saturated/
monounsaturated fatty acids (a), ratio𝜔6/𝜔3 polyunsaturated fatty acids (b),𝜔6-arachidonic acid percent of total FA content of phospholipids
(c), and 𝜔-3 eicosapentaenoic acid % of total FA content of phospholipids (d), in the groups of obese patients with metabolic syndrome (OB
w.MetS, 𝑛 = 45) andwithoutmetabolic syndrome (OBw.o.MetS, 𝑛 = 33) and of control healthy subjects (CTR, 𝑛 = 49). Values are represented
as mean (◻), standard error of themean (upper and lower limits of the box), and 1.96 × standard error (upper and lower whiskers). Intergroup
significant differences (𝑝) are indicated in each panel. Abbreviations: SAT (saturated fatty acids); MUFA (monounsaturated fatty acids);
PUFA (polyunsaturated fatty acids); C20:4 (arachidonic acid); C20:5 (eicosapentaenoic acid); and RBC (red blood cells). Techniques: gas
chromatography-mass spectrometry with selected ion monitoring (a–d).
healthy controls. C-peptide levels were highly increased in
OB w.o.MetS (𝑝 < 0.0001) while MetS values did not meet
statistical significance requirements (Figure 4(a)). PAI-1 was
dramatically higher versus CTR in MetS group (𝑝 < 0.0001,
Figure 4(b)). The increase of ATP levels in plasma activated
platelets did not reach statistical significance in the same OB
subgroup, whilst resulting to be significantly lower-than-CTR
(𝑝 < 0.01) in OB w.o.MetS (Figure 4(c)), where PAI-1 was
not increased. GIP levels were unchanged versus CTR in both
obese groups (Figure 4(e)). As expected, leptin levels were
elevated in OB w.MetS and OB w.o.MetS versus CTR (𝑝 <
0.0001), while the anti-inflammatory ghrelin levels, though
not showing any significant difference versus CTR, displayed
clearcut in-between differences (𝑝 < 0.001) in the two OB
subgroups (Figures 4(d) and 4(f)). No differences among the
three patient cohorts were registered for GLP-1, glucagon,
insulin, resistin, and visfatin (data not shown).
The significant results of themultiarray analysis of the 27-
plex panel of plasma inflammatory cytokines, chemokines,
and growth factors are shown in Figures 5(a) and 5(b).
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Figure 4: Plasma levels of selected adipokines: C-peptide (a), plasminogen activator inhibitor-1 (b), leptin (d), glucose-dependent
insulinotropic polypeptide (e), ghrelin (f), and ATP levels in platelet-enriched plasma (c), in the groups of obese patients with metabolic
syndrome (OB w.MetS, 𝑛 = 67) and without metabolic syndrome (OB w.o.MetS, 𝑛 = 45), and control healthy subjects (CTR, 𝑛 = 90). Values
are represented as mean (◻), standard error of the mean (upper and lower limits of the box), and 1.96 × standard error (upper and lower
whiskers). Intergroup significant differences (𝑝) are indicated in each panel. Abbreviations: PAI-1 (plasminogen activator inhibitor-1); PRP
(platelet-rich plasma); and GIP (glucose-dependent insulinotropic polypeptide). Techniques: multiplexed Bio-Plex Suspension Array System
(a-b, d–f), bioluminescence (c).
All the twelve proteins shown, that is, PDGF-bb, IL-6, Il-7,
Il-10, IL-4, IL-8 (Figure 5(a) (A)–(F)), IL-9, G-CFS, TNF-𝛼,
VEGF, GM-CFS, and RANTES (Figure 5(b) (A)–(F)), were
significantly higher (𝑝 < 0.05–𝑝 < 0.001) in the plasma of
OB w.MetS as compared to CTR and also to OB w.o.MetS
groups. In all cases, plasma levels in OB w.o.MetS were not
statistically different versus CTR, with the exception of a
significant increase (𝑝 < 0.0001) for PDGF-bb (Figure 5(a)
(A)), G-CFS, and RANTES (Figure 5(b) (B) and (F)).
4. Discussion
The primary goal of the present clinical laboratory trial
was to evaluate the patterns of oxidative stress, adipokines,
and inflammatory factors in two groups of obese people
with similar clinical features of obesity but with different
metabolic status. One group was clinically and biochemically
defined as having a MetS, and the other did not have as
yet all metabolic derangements characteristic for “unhealthy”
obesity (Table 1).The table shows that patients of both groups
were overweighted (BMI), had central type of obesity with fat
accumulation around the waist (Circumference), and similar
highly increased versus normal ratios of fat/lean tissue mass.
Nevertheless, the obese groups under investigation differed
substantially in the widely accepted metabolic markers of
MetS, such as dyslipidemia, insulin resistance, and borderline
fasting glucose levels attributed to prediabetes [12, 15, 16,
21]. Majority of the OB+MetS group patients suffered from
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Figure 5: (a) Plasma levels of selected cytokines/chemokines/growth factors: platelet-derived growth factor (A), interleukin 6 (B), interleukin
7 (C), interleukin 10 (D), interleukin 4 (E), and interleukin 8 (F), in the groups of obese patients withmetabolic syndrome (OBw.MetS, 𝑛 = 67)
and without metabolic syndrome (OB w.o.MetS, 𝑛 = 45) and of control healthy subjects (CTR, 𝑛 = 90). Values are represented as mean (◻),
standard error of the mean (upper and lower limits of the box), and 1.96 × standard error (upper and lower whiskers). Intergroup significant
differences (𝑝) are indicated in each panel. Abbreviations: PDGF-bb (platelet-derived growth factor); IL-6 (interleukin 6); IL-7 (interleukin
7); IL-10 (interleukin 10); IL-4 (interleukin 4); and IL-8 (interleukin 8). Techniques: multiplexed Bio-Plex Suspension Array System (A–F). (b)
Plasma levels of selected cytokines/chemokines/growth factors: interleukin 9 (A), granulocyte colony stimulating factor (B), tumor necrosis
factor-𝛼 (C), vascular endothelial growth factor (D), granulocyte-macrophage colony stimulating factor (E), regulated on activation, normal T
cell expressed and secreted (F), in the groups of obese patientswithmetabolic syndrome (OBw.MetS,𝑛 = 67) andwithoutmetabolic syndrome
(OB w.o.MetS, 𝑛 = 45), and control healthy subjects (CTR, 𝑛 = 90). Values are represented as mean (◻), standard error of the mean (upper
and lower limits of the box), and 1.96 × standard error (upper and lower whiskers). Intergroup significant differences (𝑝) are indicated in
each panel. Abbreviations: IL-9 (interleukin 9); G-CSF (granulocyte colony stimulating factor); TNF-alpha (tumor necrosis factor-𝛼); VEGF
(vascular endothelial growth factor); GM-CSF (granulocyte-macrophage colony stimulating factor); and RANTES (regulated on activation,
normal T cell expressed and secreted). Techniques: multiplexed Bio-Plex Suspension Array System (A–F).
arterial hypertension (data not shown). The large female sex
prevalence is in fact a commonoccurrence in obesity facilities
in Italy. The group of males (12 out of 112 obese subjects
included in the study) did not show peculiar differences in
the metabolic and immunologic parameters with the females
and therefore was included in the general evaluation.
There is a continuous debate over the causes and possible
mechanisms of transition from benign obesity to obesity
aggravated by serious metabolic disorders (MetS) bearing
high incidence of cardiovascular complications and type II
diabetes [9–11, 16, 19–25, 57]. Here, we attempted to elucidate
an impact of redox and adipokine homeostasis players and
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definite inflammatory factors to the effective metabolic dif-
ferences in benign obesity and unhealthy obesity complicated
withMetS. It was not surprising for us that a redox imbalance
in favour of oxidative stress with suppressed glutathione
and GST (Figure 1), higher-than-normal levels of 4-HNE
protein adducts, and luminol-dependent chemiluminescence
(Figure 2) was observed in both groups of obese people
independently on the presence of metabolic abnormalities.
In accordance with recent literature data, 4-HNE has been
found in greater-than-normal amounts in obese people [58,
59]. The aldehyde is a final product of lipid peroxidation
with diabetogenic potential through induction of insulin
resistance and capacity to disrupt adipogenic functions [58–
60]. GST protein is sensitive to 4-HNE adduct formation and
therefore may be partially inactivated by 4-HNE excess [61]
in the obese. In a loop, enzyme inactivation could sustain
the increased levels of 4-HNE observed, since GST enzyme
together with glutathione inactivates aldehydes [60, 62, 63].
Luminol-dependent chemiluminescence (CL) reflects the
capacity of ROS production by circulating granulocytes
and monocytes [64]. Since these circulating phagocytes are
primed by oxidized low-density lipoproteins (oxLDL) [65–
67] to release large amounts of ROS, it appears to be logic that
ROS production in obese subjects in general is increased. A
vicious cycle is formed when LDL are oxidized by ROS, while
oxLDL induce ROS overproduction.
The combination of low level vitamin E, activated SOD,
and inhibited CAT in the group with uncomplicated obesity
(Figures 1 and 2) allowed us to hypothesize that the high levels
of hydrogen peroxide formed in the reaction of superoxide
anion-radicals dismutation by SOD (2O
2
− + 2H+ + 2H
2
O →
2H
2
O
2
) persist due to inadequate activity of CAT, a hydrogen
peroxide decomposing enzyme (2H
2
O
2
→ 2H
2
O + O
2
).
Catalase activity is usually inhibited by excess H
2
O
2
, as well
as by 4-HNE, which forms aldehyde-protein adducts with
the enzyme, thus inactivating its active centre [61, 68, 69].
Hydrogen peroxide belongs to stable reactive oxygen species
which, in the presence of transition metals, could be easily
converted into hydroxyl radicals (H
2
O
2
+ Fe+n → 2OH∙),
classical initiators of lipid peroxidation chain reaction. Under
these circumstances, 𝛼-tocopherol plays a classical role of
sacrificing antioxidant being consumed in the process of
interruption of the chain reaction in lipid compartments [70–
72].
Of great importance, GPX is hyperactivated in the group
with MetS exclusively (Figure 1). PUFA in the membrane
phospholipids or in circulating lipoproteins are subjected to
intense enzymatic (12/15 lipoxygenase) or nonenzymatic free
radical-driven lipid peroxidation, under certain pathological
conditions such as inflammation, obesity, or atherosclerosis
[73]. Both types of lipid oxidation result in the formation of
highly reactive lipid hydroperoxides (LOOH), proinflamma-
tory leukotrienes among them, which are neutralised by GPX
(mainly, by isoform Gpx4) [74], GST [75], peroxireductase
VI, and aldo-keto-reductases [73]. LOOH [73, 76] and small
end-products of lipid peroxidation such as 4-HNE and other
aldehydes (malonyldialdehyde, acrolein, etc.) transported by
activated granulocytes/monocytes may facilitate and main-
tain generalised inflammation [77–79]. Of interest, successful
anti-inflammatory therapy of psoriasis patients with TNF-
𝛼 antibodies led to suppression of GPX activity, while in
nonresponders to the therapy, GPX activity was further stim-
ulated [80].
In addition to the possible pathogenic role(s) of oxidative
processes in lipids, a significant elevation of monounsatu-
rated fatty acids (MUFA) in erythrocyte membranes assessed
by the decreased ratio of saturated FA/MUFA was shown for
both experimental obese groups, while increased content of
𝜔-6 versus decreased 𝜔-3 membrane-bound FA was found
in uncomplicated obesity group only (Figure 3). Membrane-
bound MUFA are considered as a strong proinflammatory
factor in obesity because their biosynthesis is associated with
hyperactivated enzyme stearoyl-delta9-desaturase [81, 82].
The combination of two factors, highly increased MUFA
and PAI-1 (Figure 4), observed in the Ob+MetS group is
associated with the increased risk of cardiovascular diseases,
high blood pressure [83], and the elevated coagulation rates
in MetS [84].
Adipose tissue was considered as a mere energy storage
until the first adipokine, a bioactive product synthesised
within and released from adipose tissue, was identified in
1994 [27].This very first adipokine was leptin, levels of which
are highly increased in obese people (Figure 4 and [85, 86]).
Adipokines control distinct essential physiological processes,
such as appetite and satiety, energy metabolism, endothelial
function, hemostasis, blood pressure, insulin secretion and
sensitivity, adipogenesis, adipocyte functions, and fat dis-
tribution [29]. Among the more than 600 putative adipoki-
nes, there are numerous proinflammatory mediators, includ-
ing interleukins, tumor necrosis factor- (TNF-) alpha, che-
mokines, and growth factors [87, 88]. A distinct adipokine
pattern associated with body weight includes insulin, tri-
glycerides, leptin, PAI-1, chemerin, MCP-1, and retinol-bind-
ing-protein-4 (RBP-4) [86]. Some adipokines, such as adi-
ponectin, leptin, chemerin, visfarin, and PAI-1, are produced
exclusively by adipose tissue, while others, tumor necrosis
factor- (TNF-) alpha, interleukins, chemokines, and growth
factors, could be produced by circulating blood leukocytes,
tissue macrophages, keratinocytes, and other cells. There-
fore, blood levels of these factors reflect not only their
release from adipose tissue but also a significant contribution
of circulating leukocytes, cells-effectors of inflammatory
responses in the organism, and endothelial cells. Out of all
pure adipokines, plasma levels of which were measured in
the study; exclusively leptin, a marker of obesity, exhibited
higher-than-normal values in both obese groups (Figure 4),
while visfatin and resistin remained within the normal range
(data not shown). Another adipokine PAI-1 produced in
visceral and not in subcutaneous adipose tissue was over-
expressed in patients with MetS; its high levels are connected
with high risk of thrombosis [84]. A clearcut proinflam-
matory pattern of cytokines (IL-4, IL-6, IL-7, and IL-9),
chemokines (IL-8), growth factors (VEGF, PDGF, G-CSF,
GV-CSF), and TNF-𝛼was found in obese subjects withMetS.
As an adaptive reaction, the expression of anti-inflammatory
IL-10 was also increased (Figures 5(a) and 5(b)). These
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findings corresponded to an assumption that MetS is a path-
ology characterised by generalised chronic inflammation [2,
4, 31, 89–91].
Of major relevance is the contribution of TNF-𝛼 to
metabolic syndrome. TNF-𝛼 expression was found to be
increased in the adipocytes of obese animals, and its neu-
tralisation by a TNF-𝛼-specific soluble antibody led to the
improvement of insulin sensitivity [92]. These observations
were then confirmed in obese and diabetic humans [93].
Noteworthy, the major source of TNF-𝛼 as well as of multiple
cytokines and chemokines in obesity are phagocytes, not
adipocytes [94]. The therapy with anti-TNF-𝛼 antibodies
resulted in attenuation of MetS symptoms in general [95]
and decrease of GPX activity to neutralise LOOH and toxic
aldehydes [80]. All these inflammation-related cytokines
could be overproduced by circulating leukocytes primedwith
LDL and free fatty acids (FFA) [67].
Of note, obesity itself was not connected to abnormal
plasma mediators of inflammation with the exception of
RANTES, which was remarkably increased in the OB group.
We assume that RANTES could be a key molecular target
to interrupt an undesired transition to MetS in obese peo-
ple. Regulation of leukocyte activation and migration into
tissues by chemokines like RANTES and similar monocyte
chemotactic protein-1 (MCP-1) are recognised as important
factors in the induction of acute and chronic inflammation
[96]. RANTES has been shown to stimulate T-lymphocyte
extravasation as well as monocyte oxidative metabolism and
recruitment to lungs, kidney, liver, skin, and other tissues
[97]. The inhibition of RANTES and MCP-1 with corre-
sponding antibodies or lowmolecular weight antagonists has
been suggested and successfully applied in many pathologies
accompanied by chronic inflammation [98]. RANTES may
represent a valuable target for the prevention of MetS setting
as well as for diagnostic purposes.
5. Conclusions
On the grounds of the results obtained, we hypothesised that
as a primary step of the transition from the benign obesity to
obesity complicated with MetS there could be a long-lasting
priming of circulating phagocytes by excessive amount of
oxLDL. The primed granulocytes and monocytes produce
large amount of ROS and redox-dependent proinflammatory
cytokines. Primed leukocytes in benign obesity overexpress
chemokines like RANTES, thus prompting leukocyte migra-
tion into tissues, for example, in adipose tissue, pancreas,
muscles, and liver, which are target organs for the initiation
and maintenance of metabolic derangements characteristic
for MetS (the first loop of transition). Subsequently, ROS-
mediated formation of LOOHand toxic end-products of lipid
peroxidation occurs. These highly reactive products induce
adipogenesis and fat production by adipocytes [65–67, 99–
101], which creates a second self-sustained pathological loop
of increased fat production and accumulation → increased
fatty acid oxidation → chronic proinflammatory pattern
formation → redox-dependent derangement of antioxidant
and detoxifying systems → redox-dependent derangement
of insulin sensitivity → redox-dependent dyslipidemia →
MetS. Upregulated GPX could be an early pathogenic marker
of MetS setting, as a unique defense against hydrogen perox-
ides and their metabolites with a pathogenic role for MetS in
the obese.
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